Results 151 to 160 of about 4,832 (178)

Benralizumab: for asthma, not yet for COPD

The Lancet Respiratory Medicine, 2014
Asthma and chronic obstructive pulmonary disease (COPD) are two distinct, chronic, inflammatory respiratory diseases.1,2 Asthma develops early in life, mainly in atopic individuals, and is characterised by airway hyper-responsiveness and recurrent wheezing due to a chronic inflammation of the airways caused by a CD4, T-helper type-2, eosinophilic ...
openaire   +3 more sources

Benralizumab

Reactions Weekly, 2021
openaire   +2 more sources

Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years

Journal of Allergy and Clinical Immunology: in Practice, 2021
Stephanie Korn, Arnaud Bourdin, Borja G Cosio   +2 more
exaly  

Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma

Biomedicine and Pharmacotherapy, 2020
Corrado Pelaia, Maria TERESA Busceti, Claudia Crimi   +2 more
exaly  

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study

Journal of Clinical Medicine, 2023
Raffaele Campisi, Santi Nolasco, Luisa Ricciardi   +2 more
exaly  

Benralizumab

Drugs of the Future, 2014
openaire   +1 more source

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

Chest, 2021
Jaideep Dhariwal, Grainne D'Ancona, Abdel Douiri   +2 more
exaly  

Effect of Benralizumab in Patients With Severe Eosinophilic Asthma and Chronic Rhinosinusitis With Nasal Polyps: A Case Series

American Journal of Rhinology and Allergy, 2021
Chandala Chitguppi, Prachi Patel, Kira Murphy   +2 more
exaly  

Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis

Respiratory Medicine, 2020
Diego Bagnasco, Luisa Brussino, Marco Bonavía   +2 more
exaly  

Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma

Expert Opinion on Biological Therapy, 2012
William J Calhoun
exaly